Skip to content
Carocell Bio

Lead programme · JEL0305

Atopic dermatitis research

JEL0305 is the peptide that leads Carocell Bio’s current dermatitis material: a topical formulation with nanoparticle delivery, studied in cellular assays and in human skin biopsies outside the body.

Preclinical & ex vivo research

Why atopic dermatitis

Atopic dermatitis (eczema) is a chronic inflammatory skin condition. The company’s current pages concentrate its development effort on this indication.

The original pages also contain educational commentary on existing treatments and market projections. These are dated company content, not current clinical guidance, and are not reproduced here.

JEL0305

Published figures

The figures below are reproduced exactly as published by the company. Values have not been re-plotted, derived or summarised.

Company-reportedTNF-α (pg/mL) across formulation conditions at T0, T4 4°C and T4 RT, as published on the company’s atopic dermatitis page. Source (opens in a new tab)Figure reproduced unmodified as published by the company. Not independently validated.

AD figure 1: TNF-α by formulation condition

Company-reportedCompany slide: JEL0305 in human lymphocytes — inflammation (TNF-α) and p38α activation after stimulation, as published. Source (opens in a new tab)Figure reproduced unmodified as published by the company. Not independently validated.

AD figure 2a: JEL0305 in human lymphocytes

Company-reportedCompany table: day-3 comparison of skin biopsy tissue (normal skin, untreated control, clobetasol propionate steroid, JEL0305 high dose), with histology, cytokine and T-cell proliferation measures, as published. Subject 001. Source (opens in a new tab)Figure reproduced unmodified as published by the company. Not independently validated.

AD figure 3: day-3 skin biopsy comparison table

Limits of this evidence

  • Ex vivo biopsy studies use tissue outside the body; they are not clinical trials in treated patients.
  • A comparison with a steroid in tissue does not establish comparative efficacy or safety in patients.
  • No clinical phase is established. ClinicalTrials.gov searches for “JEL0305” and “Carocell” (13 Oct 2026) returned no studies — this does not cover every registry.
Research directions: recurrence & skin ageing